Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS

Business teamwork. Collaboration of entrepreneurs to achieve success. Partners communicate with each other and discuss cooperation. Cartoon flat vector illustration isolated on light background

NextGen

In Biotech’s ‘Moribund’ Market, What Does It Take To Survive?

BioSpace’s NextGen companies are rising in one of the most confounding biotech markets ever experienced. Executives sounded off on how to keep your head above water during our webinar, Are We There Yet?

May 21, 2025

6 min read

Annalee Armstrong

BROUGHT TO YOU BY PLIANCY

Webinar: Are We There Yet? Surviving and Thriving in the Never-ending Biotech Downturn

BioSpace sits down with four NextGen companies that are thriving despite a multi-year down period. You will hear about ways they are defying the odds to churn out clinical data that may finally provide the industry with a ladder out. Watch now.

May 21, 2025

1 min read

BioSpace Insights

Collaboration

Genentech Bets Again on Orionis With Potential $2B+ in Crowded Molecular Glue Space

Roche, along with Bristol Myers Squibb, Novo Nordisk, AbbVie, Eli Lilly and others, is making inroads into molecular glues to use in cancer, immunology and other applications.

May 21, 2025

2 min read

Tristan Manalac

Government

RFK Claims Ignorance About HHS Research, Clinical Trial Cuts in Hearing

After a tense exchange, Senator Patty Murray (D-WA) told Kennedy that by implementing sweeping cuts to the HHS, he is “enacting his budget,” which “Congress has not passed.”

May 21, 2025

2 min read

Tristan Manalac

A person and a group of people are separated by a yellow line. Establishing contact. Distrust. Quarantine. Distance with strangers. Barrier to understanding, difficult integration. Rejection, refusal.

Lymphoma

Roche’s Genentech Fails to Win Adcomm Backing for Columvi Expansion

The ODAC cited concerns with patient populations in clinical trials used to support the proposed expansion. Johnson & Johnson fared better, with the FDA’s cancer advisors voting to recommend Darzalex in patients with a certain type of multiple myeloma.

May 21, 2025

2 min read

Tristan Manalac

Podcast

Pfizer’s $6B China Deal, Drug Pricing and FDA’s New COVID Vaccine Plan

China continues to be a source of innovation as Pfizer strikes biggest pact yet; HHS provides more info on Trump’s Most Favored Nation executive order; FDA Commissioner Marty Makary and CBER director Vinay Prasad reveal new COVID-19 vaccine strategy following Novavax approval; ODAC underway after chaotic planning; more.

May 21, 2025

2 min read

Heather McKenzie

Conversion creative ideas into money with innovation machine, startup opportunity to earn money by motenization. Light bulbs in funnel converts to coins flowing through tap cartoon vector illustration

Venture capitalists

The Top 5 Most Active Corporate VCs in Pharma

BioSpace examines the busiest corporate venture capital arms in the pharmaceutical industry. Novo Holdings, which made headlines last year with its $16.5 billion Catalent buy, topped the list.

May 21, 2025

5 min read

Annalee Armstrong

Metal pipe with empty flange covering the end. A PVC pipe with metal joins and flanges with bolts.

Opinion

Evolving Market Pressures Force Biopharma Companies to Cut Assets Early

From a higher bar for regulatory clearance to pricing limitations, drug development is more expensive than ever. This has led firms to make tough pipeline decisions early in the development process. The result may be costly for all of us.

May 21, 2025

5 min read

Michael N. Abrams